Akeso, Inc. (HK:9926) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akeso, Inc. has announced that China’s National Medical Products Administration (NMPA) approved the supplemental New Drug Application for cadonilimab as a first-line treatment for advanced gastric cancer, marking a significant advancement in immunotherapy options for the disease. The drug, which addresses the efficacy gap in patients with low or negative PD-L1 expression, demonstrated a significant improvement in overall survival during Phase III clinical trials. This approval may pave the way for broader applications in various cancer treatments, as the company is conducting multiple clinical trials for different indications.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.